Ethiopia

in page functions
[French]
Ethiopia
Total population (2018) 106,863,109
Birth cohort (2018) 3,255,213
Surviving Infants (surviving to 1 year per year, 2018) 3,119,128
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 41/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 59/1000
World Bank Index, IDA (2015) 3.49
Gross Nation Income (per capita US$, 2015) 590
Co-financing group (2018) Initial self-financing
No. of districts/territories (2017) 854

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Ethiopia

Type of support

Approvals

2001-2023 (US$)
(26 Sep 2018)

Commitments

2001-2023 (US$)
(26 Sep 2018)

Disbursements

2000-2018 (US$)
(26 Sep 2018)

% Disbursed

(26 Sep 2018)
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Total $988,194,310 $1,246,083,648 $961,402,896
Cash Support (CASHSUPP) $169,668 $194,668 $169,668 100%
Civil Society Organisation support (CSO) $3,162,420 $3,162,420 $3,262,420 103%
Cold Chain Equipment Optimisation Platform (CCEOP) $4,747,678 $20,875,664
Health system strengthening (HSS 1) $76,493,935 $76,493,935 $76,493,935 100%
Health system strengthening (HSS 2) $61,405,575 $61,405,575 $61,405,575 100%
Health system strengthening (HSS 3) $63,165,802 $101,085,454 $36,176,057 57%
Health system strengthening (HSS 3 - PBF) N/A
HPV (NVS) $12,659,500 $40,478,500 $4,649,580 37%
HPV Demo (NVS) $147,439 $147,439 $147,439 100%
HPV MAC (NVS) $50,803,000 N/A
HPV MAC - Op costs (OPC) $4,195,200 N/A
Immunisation services support (ISS) $23,445,320 $23,445,320 $17,813,320 76%
Injection Safety Devices (NVS) $2,276,655 $5,626,155 $2,737,506 120%
Injection safety support (INS) $2,696,697 $2,696,697 $2,696,697 100%
IPV (NVS) $10,426,463 $10,426,463 $9,497,422 91%
Measles 1st and 2nd dose (NVS) $714,500 $1,954,500 $799,488 112%
Measles SIA (NVS) $8,458,031 $8,458,031 $8,458,031 100%
Measles SIA - Operational costs (OPC) $14,534,328 $14,534,328 $14,534,328 100%
Meningitis A - campaign (NVS) $43,030,647 $43,030,647 $44,310,479 103%
Meningitis A - operational costs (OPC) $33,779,677 $33,779,677 $33,779,677 100%
Penta (NVS) $236,504,887 $255,927,887 $238,802,600 101%
Pneumo (NVS) $309,645,911 $380,731,411 $325,426,535 105%
Rotavirus (NVS) $69,996,471 $95,897,971 $69,509,599 99%
Vaccine Introduction Grant (VIG) $10,732,706 $10,732,706 $10,732,540 100%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Ethiopia DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2017)

Grade of confidence


N/A
DTP3 - Official country estimates (2017) 96%
M:F sex ratio at birth (2018) 1.04
Household survey: DTP3 coverage for male (2010) 34.30%
Household survey: DTP3 coverage for female (2010) 38.80%
Household survey: Last DTP3 survey (2010) 37%
% districts achieving > 80% DTP3 coverage (2017) 78%
% districts achieving < 50% DTP3 coverage (2017) 4%
MCV WHO/UNICEF estimates (2017) 65%

Breakdown of support

Non-vaccine support Vaccine support
27% 73%
$257,064,217 $704,338,679

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Ethiopia

10 September 2018

Vaccine heroes exhibit

Vaccine Heroes

A new Gavi photo exhibition in Geneva celebrates the health workers, campaigners, scientists and parents who reach millions of children with life-saving vaccines every year.

19 May 2018

Kenya HPV

Gavi welcomes call for coordinated global action against cervical cancer

Alliance pledges to continue support for vaccines.

09 January 2018

IFFIm Chair - René Karsenti and Cyrus Ardalan

Cyrus Ardalan becomes new Chair of IFFIm Board

Ardalan succeeds René Karsenti, who oversaw nearly US$ 2.5 billion in bond issuances, entry into Sukuk markets.

Disclaimer: the boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of Gavi, the Vaccine Alliance concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

close icon

modal window here